TEE
AVTX icon

Tibra Equities Europe’s Avalo Therapeutics AVTX Stock Holding History

Tibra Equities Europe’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-12
Closed -$210K – 258
2019
Q1 		$210K Buy
+12
New +$180K 0.02% 371

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Tibra Equities Europe's AVTX Position: Q2 2019 in Review

Tibra Equities Europe sold out of Avalo Therapeutics (AVTX) in Q2 2019, closing a stake of 12 shares — an estimated $210K sold.

Tibra Equities Europe first reported a position in AVTX in Q1 2019 and held it in 1 quarter. The position peaked at $210K in Q1 2019. 36 funds tracked by Wall St. Rank hold AVTX as of Q2 2019.

  • Tibra Equities Europe reported no remaining Avalo Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Tibra Equities Europe sold 12 Avalo Therapeutics shares in Q2 2019, an estimated $210K.
  • Tibra Equities Europe first reported a position in Avalo Therapeutics in Q1 2019 and held it in 1 quarter.
  • Tibra Equities Europe's Avalo Therapeutics position peaked at $210K in Q1 2019.
  • 36 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2019.

Based on Tibra Equities Europe's 13F filing for Q2 2019, filed 1 Aug 2019.